| NCT04365868 | Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2020-06-22 | 2025-09-30 | 2025-03-11 |
| NCT04332432 | A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment | COMPLETED | PHASE1 | 2020-06-16 | 2022-03-09 | 2022-03-09 |
| NCT02421094 | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis | COMPLETED | PHASE2 | 2015-09 | 2016-09-27 | 2016-09-27 |
| NCT02407041 | An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis | COMPLETED | PHASE2 | 2015-09 | 2018-03 | 2018-03 |
| NCT02462967 | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis | COMPLETED | PHASE2 | 2015-06 | 2017-10 | 2017-10 |
| NCT01899859 | Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis | COMPLETED | PHASE1 | 2013-07 | 2015-02 | 2015-02 |
| NCT00388700 | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer | WITHDRAWN | PHASE2 | 2006-10 | 2009-06 | 2009-06 |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer | WITHDRAWN | PHASE2 | 2006-09 | 2009-06 | 2009-06 |
| NCT00110721 | GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer | TERMINATED | PHASE2 | 2005-05 | 2008-02 | 2007-06 |
| NCT00054977 | Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors | COMPLETED | PHASE1 | 2003-02 | 2006-09 | 2005-04 |